News about Market

Worldwide Clinical Trials to Acquire Catalyst Clinical Research

Worldwide Clinical Trials has entered into a definitive agreement to acquire Catalyst Clinical Research, a move aimed at expanding its functional service provider capabilities, strengthening its global site network, boosting oncology expertise, and accelerating technology integration to enhance efficiency and transparency for customers.

Market | 21/01/2026 | By News Bureau |  365

JB Chemicals Delivers Strong Q3 FY26 Results with Double-Digit Growth

JB Chemicals and Pharmaceuticals Ltd (JB Pharma) reported a strong financial performance for the third quarter of FY26, with consolidated revenue rising to INR 1,065 crore, an increase of around 11 percent compared to the same quarter last year.

Market | 20/01/2026 | By Darshana |  286

Syngene Renews Long-Term Research Alliance with Bristol Myers Squibb Until 2035

Syngene International has extended its long-term research collaboration with Bristol Myers Squibb until 2035, expanding the partnership to cover integrated services across the drug development lifecycle, from discovery and translational sciences to manufacturing, clinical trials and commercialisation support.

Market | 20/01/2026 | By News Bureau |  144

Rakuten Medical and LOTTE Biologics Sign Manufacturing Deal for Global Oncology Programme

Rakuten Medical has entered into a manufacturing agreement with LOTTE Biologics under which LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical’s global clinical development programmes and future commercialisation in oncology.

Market | 19/01/2026 | By News Bureau |  295

Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma

Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.

Market | 16/01/2026 | By News Bureau |  164

Biocon Raises INR 4,150 Crore via QIP

Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.

Market | 15/01/2026 | By News Bureau |  189

Genethon Partners with AskBio on Pompe Gene Therapy

The licensing deal enables AskBio to advance the clinical development of Genethon’s investigational gene therapy for Pompe disease through an industry partnership.

Market | 15/01/2026 | By News Bureau |  238

Amneal Unveils New Brand to Expand Access to Medicines

The refreshed brand features a new visual identity and “Signature” logo that reflects trust in healthcare, patient impact, and Amneal’s focus on expanding access to medicines across complex therapeutic areas.

Market | 15/01/2026 | By News Bureau |  327

Dr Reddy's Launches First-to-Market Olopatadine Ophthalmic Solution in US

With the US launch of its first-to-market OTC Olopatadine 0.7 percent eye drops, Dr Reddy’s expands access to allergy relief for itchy eyes caused by pollen and other common allergens.

Market | 15/01/2026 | By News Bureau |  196

Bayer to Enter Molecular Imaging, Acquires Pan-Amyloid Radiotracers from Attralus

By acquiring AT-01 and AT-05 from Attralus, Bayer strengthens its molecular imaging and cardiovascular precision medicine portfolio, targeting earlier and more accurate diagnosis of amyloidosis.

Market | 14/01/2026 | By News Bureau |  322